Skip to main content

In Silico Drug Discovery Market Size Worth USD 11.68 Billion in 2032 | Emergen Research

The growing need for partnerships and collaboration among market players and the increasing need for cost-effective solutions will drive the In Silico Drug Discovery Market

Vancouver, Nov. 15, 2023 (GLOBE NEWSWIRE) — The global In Silico Drug Discovery Market is forecasted to be worth USD 11.68 Billion by 2032, according to a current analysis by Emergen Research. The technology is useful in finding new molecules from the molecule library, identify drug targets, and develop personalized medicines in the industry. The application of computers makes the whole process quick and cost-effective. Several factors are aiding in the growth of the market, such as an increase in the number of people suffering, the flourishing healthcare industry, along with manufacturers’ approach towards reducing the overall cost associated with drug development.

Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/373

The growing adoption of cloud-based applications and the expiration of patented drugs will pave the way for new generic and OTC medicines, which will influence market demand. The advancement in deep learning and machine learning will allow pharmaceutical companies to reorganize molecule binding properties with high accuracy

High level of investment in the development of healthcare infrastructure by the government, growing awareness regarding the benefits of computer software in solving complex situations will support the demand for the market. Moreover, the strategic approach to lower the cost of drug discovery will also augment the revenue of the market.

Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @ https://www.emergenresearch.com/request-discount/373

Scope of Research

Report Details Outcome
The market size value in 2019 USD 2.38 Billion
CAGR (2023 – 2032) 13.0%
The revenue forecast in 2032 USD 11.68 Billion
Base year for estimation 2022
Forecast period 2023 – 2032
Quantitative units Volume in Tons, Revenue in USD Thousand, and CAGR from 2023 to 2032
Report coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered Workflow, Product, Type Of Large Molecule, End-User, Region.
Regional scope North America; Europe; Asia Pacific; Central & South America; MEA.
Country scope U.S.; Canada; Mexico; U.K.; Germany; France; Italy; Spain; China; India; Japan; South Korea; Brazil; Saudi Arabia; South Africa; Turkey.
Key companies profiled Certara USA, Inc., Albany Molecular Research Inc., Chemical Computing Group ULC, Charles River, Dassault System (Biovia), Collaborative Drug Discovery Inc., Evotec A.G., ICAGEN, Inc., GVK Biosciences Private Limited, and Novo Informatics Pvt. Ltd.
Customization scope 10 hrs of free customization and expert consultation

MAJOR COMPANIES and Market Share Analysis

The market for In Silico Drug Discovery is fairly consolidated, with few small as well as medium-sized manufacturers, which account for a major global share of the market. The manufacturers involved in the market are desegregated across the value chain. The key companies of the market are well-equipped with large manufacturing facilities and are also engaged in various research & development activities. Some of the prominent players in the In Silico Drug Discovery industry include:

  • Certara USA, Inc.
  • Albany Molecular Research Inc.
  • Chemical Computing Group ULC
  • Charles River
  • Dassault System (Biovia)
  • Collaborative Drug Discovery, Inc.
  • Evotec A.G.
  • ICAGEN, Inc.
  • GVK Biosciences Private Limited
  • Novo Informatics Pvt. Ltd.

In October 2020, Synthace Ltd announced the launch of the cloud-based software platform for improving and automating the success rate of the biological processes of the enzyme-linked immunosorbent assay (ELISA). The Software Antha now permits researchers to flexibly design and execute automated ELISA protocols.

Strategic Development

  • In June 2020, GNS Healthcare announced the launch of an in silico multiple myeloma patient. GeminiTM is a highly accurate computer model for drug response and disease progression at an individual patient level.

Direct Order Can Be Placed Through This Link [Exclusive Copy] @
https://www.emergenresearch.com/select-license/373

Key Highlights From The Report

  • In silico approaches to nucleic acid have been to study the duplex DNA in complexes with proteins and other structures. The overall purpose of the work was to provide stability, recognition, and energetics of binding and dynamic behavior of these DNAs.
  • The Software as a Service (Cloud) computing opens up different ventures for small and medium biotechnology laboratories, and it needs to perform analysis of bioinformatics in an effective and flexible manner. Hybrid cloud is particularly useful as it incorporates the scalability provided by the public clouds with improved control and customizations provided by the private cloud.

Browse Full Report Description + Research Methodology + Table of Content + Infographics@
https://www.emergenresearch.com/industry-report/in-silico-drug-discovery-market

Emergen Research has segmented into the global In Silico Drug Discovery Market on the workflow, product, type of large molecule, end-user, and region:

  • Workflow Outlook (Revenue, USD Billion; 2019 – 2032)
    • Discovery
      1. Target Identification
        • Reverse Docking
        • Bioinformatics
        • Protein Structure Prediction
      2. Target Validation
      3. Lead Discovery
        • Pharmacophore
        • Library Design
    • Pre-Clinical Tests
    • Clinical Trials
  • Product Outlook (Revenue, USD Billion; 2019 – 2032)
    • Consultancy as a Service
    • Software as a Service (Cloud)
    • Software
  • Type of Large Molecule Outlook (Revenue, USD Billion; 2019 – 2032)
    • Proteins
    • Antibodies
    • Nucleic Acids
    • Peptides
    • Vectors
  • End-User Outlook (Revenue, USD Billion; 2019 – 2032)
    • Contract Research Organizations
    • Pharmaceutical Industry
    • Academic and Research Institutes
    • Others
  • Regional Outlook (Revenue, USD Billion; 2019 – 2032)
    • North America
      1. U.S.
      2. Canada
    • Europe
      1. Germany
      2. UK
      3. France
      4. BENELUX
      5. Rest of Europe
    • Asia Pacific
      1. China
      2. Japan
      3. South Korea
      4. Rest of APAC
    • Latin America
      1. Brazil
      2. Rest of LATAM
    • MEA
      1. Saudi Arabia
      2. UAE
      3. Rest of MEA

Curated Reports You Shouldn’t Miss: Dive In Now!

Surgical Imaging Market, By Device Type (Endoscopy, Angiography, and Others), By Technology (Image Intensifier and Flat Panel Detector), By Modality (Computed Tomography, Ultrasound, and Others), By Application, and By Region Forecast to 2032

Biopsy Devices Market, By Product Type (Needle-based Biopsy Guns), By Application (Breast Biopsy and Prostate Biopsy), By Imaging Technology, By End-use, and By Region Forecast to 2032

Computed Tomography Scanner Market, By Type (Stationary CT Scanners and Portable CT Scanners), By Device , By Technology, By Application, By End-use, And By Region Forecast to 2032

Pediatric Perfusion Products Market, By Product Type (Pediatric Cannulae, Pediatric Centrifugal Blood Pumps, Pediatric Oxygenators, and Others), By End-Use (Hospitals, Cardiac Centers, and Others), By Region Forecast to 2032

Ventilator Filters Market, By Product Type (Bacterial/Viral Filters, Hygroscopic Condenser Humidifier (HCH) filters, and Others), By Application, By End-Use (Hospitals & Clinics, Home Care Settings, and Others), and By Region Forecast to 2032

Telemedicine Market, By Type (Tele Hospitals, Tele Homes, and Others), By Technology (Store-and-Forward, Real-Time, and Others), By End-Use, By Component, By Delivery Mode, and By Region Forecast to 2032

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: https://www.emergenresearch.com/

Direct Line: +1 (604) 757-9756

E-mail: sales@emergenresearch.com

Explore Our Japanese Version: In Silico Drug Discovery Market

Explore Our Blogs and Insights Section: https://www.emergenresearch.com/insights

Read our Press Release @ https://www.emergenresearch.com/press-release/global-in-silico-drug-discovery-market

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.